Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim
Express Scripts

Last Updated: June 4, 2023

Details for Patent: 9,902,714

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Which drugs does patent 9,902,714 protect, and when does it expire?

Patent 9,902,714 protects BALVERSA and is included in one NDA.

This patent has thirty-six patent family members in thirty-three countries.

Summary for Patent: 9,902,714
Title:Quinoxaline derivatives useful as FGFR kinase modulators
Abstract: The invention relates to new quinoxaline derivative compounds of formula (I), to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer. ##STR00001##
Inventor(s): Vermeulen; Wim (Vosselaar, BE), Hostyn; Steven Anna (Hove, BE), Cuyckens; Filip Albert Celine (Aartselaar, BE), Jones; Russell Mark (Binningen, CH), Broggini; Diego Fernando Domenico (Zurich, CH)
Assignee: ASTEX THERAPEUTICS LTD (Cambridge, GB)
Application Number:15/128,345
Patent Claim Types:
see list of patent claims
Composition; Compound; Process;

Drugs Protected by US Patent 9,902,714

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Janssen Biotech BALVERSA erdafitinib TABLET;ORAL 212018-001 Apr 12, 2019 RX Yes No ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Janssen Biotech BALVERSA erdafitinib TABLET;ORAL 212018-002 Apr 12, 2019 RX Yes No ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Janssen Biotech BALVERSA erdafitinib TABLET;ORAL 212018-003 Apr 12, 2019 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 9,902,714

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
14161820Mar 26, 2014
PCT Information
PCT FiledMarch 26, 2015PCT Application Number:PCT/EP2015/056507
PCT Publication Date:October 01, 2015PCT Publication Number: WO2015/144803

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.